TFFP - Progenity: The Transition Is Well Under Way

• Progenity is transitioning away from molecular testing operations to focus on the development of biotherapeutics.
• In this respect, the third quarter's financials were pivotal to the transformation strategy as it translated into a reduction in operational expenses as planned.
• With its oral delivery mechanism, Gastrointestinal targeted therapies, and women's health tests, the company has potential despite generating meager revenues.
• However, the stock is also subject to volatility risks as past performance shows it fluctuating amid "social media buzz".
• Comparison with TFF Pharmaceuticals points to undervaluation as in the same way as the latter, Progenity could benefit from licensing revenue, and the forthcoming Preecludia publication could constitute a catalyst for upside.

For further details see: